All Title Author
Keywords Abstract

Marine Drugs  2013 

Anti-Microbial, Anti-Biofilm Activities and Cell Selectivity of the NRC-16 Peptide Derived from Witch Flounder, Glyptocephalus cynoglossus

DOI: 10.3390/md11061836

Keywords: fish peptide, NRC-16, antimicrobial peptide, antibiofilm peptide, eukaryotic membrane, phosphatidylcholine, cholesterol, sphingomyelin

Full-Text   Cite this paper   Add to My Lib

Abstract:

Previous studies had identified novel antimicrobial peptides derived from witch flounder. In this work, we extended the search for the activity of peptide that showed antibacterial activity on clinically isolated bacterial cells and bacterial biofilm. Pseudomonas aeruginosa was obtained from otitis media and cholelithiasis patients, while Staphylococcus aureus was isolated from otitis media patients. We found that synthetic peptide NRC-16 displays antimicrobial activity and is not sensitive to salt during its bactericidal activity. Interestingly, this peptide also led to significant inhibition of biofilm formation at a concentration of 4–16 μM. NRC-16 peptide is able to block biofilm formation at concentrations just above its minimum inhibitory concentration while conventional antibiotics did not inhibit the biofilm formation except ciprofloxacin and piperacillin. It did not cause significant lysis of human RBC, and is not cytotoxic to HaCaT cells and RAW264.7 cells, thereby indicating its selective antimicrobial activity. In addition, the peptide’s binding and permeation activities were assessed by tryptophan fluorescence, calcein leakage and circular dichroism using model mammalian membranes composed of phosphatidylcholine (PC), PC/cholesterol (CH) and PC/sphingomyelin (SM). These experiments confirmed that NRC-16 does not interact with any of the liposomes but the control peptide melittin did. Taken together, we found that NRC-16 has potent antimicrobial and antibiofilm activities with less cytotoxicity, and thus can be considered for treatment of microbial infection in the future.

References

[1]  Park, S.C.; Park, Y.; Hahm, K.S. The role of antimicrobial peptides in preventing multidrug resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 2011, 12, 5971–5992, doi:10.3390/ijms12095971.
[2]  Dzidic, S.; Suskovic, J.; Kos, B. Antibiotic resistance mechanisms in bacteria: Biochemical and genetic aspects. Food Technol. Biotechnol. 2008, 46, 11–21.
[3]  Wright, G.D. Bacterial resistance to antibiotics: Enzymatic degradation and modification. Adv. Drug Deliv. Rev. 2005, 57, 1451–1470, doi:10.1016/j.addr.2005.04.002.
[4]  Lambert, P.A. Bacterial resistance to antibiotics: Modified target sites. Adv. Drug Deliv. Rev. 2005, 57, 1471–1485, doi:10.1016/j.addr.2005.04.003.
[5]  Kumar, A.; Schweizer, H.P. Bacterial resistance to antibiotics: Active efflux and reduced uptake. Adv. Drug Deliv. Rev. 2005, 57, 1486–1513, doi:10.1016/j.addr.2005.04.004.
[6]  Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections. Science 1999, 284, 1318–1322, doi:10.1126/science.284.5418.1318.
[7]  Drenkard, E.; Ausubel, F.M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002, 416, 740–743, doi:10.1038/416740a.
[8]  Ehrlich, G.D.; Veeh, R.; Wang, X.; Costerton, J.W.; Hayes, J.D.; Hu, F.Z.; Daigle, B.J.; Ehrlich, M.D.; Post, J.C. Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 2002, 287, 1710–1715, doi:10.1001/jama.287.13.1710.
[9]  Singh, P.K.; Schaefer, A.L.; Parsek, M.R.; Moninger, T.O.; Welsh, M.J.; Greenberg, E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407, 762–764, doi:10.1038/35037627.
[10]  Perron, C.G.; Zasloff, M.; Bell, G. Experimental evolution of resistance to an antimicrobial peptide. Proc. Biol. Sci. 2006, 273, 251–256, doi:10.1098/rspb.2005.3301.
[11]  Yeaman, M.R.; Yount, N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55, 27–55, doi:10.1124/pr.55.1.2.
[12]  Giuliani, A.; Pirri, G.; Nicoletto, S.F. Antimicrobial peptides: An overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2007, 2, 1–33, doi:10.2478/s11535-007-0010-5.
[13]  Diaz, G.A. Defensins and cystein rich peptides: Two types of antimicrobial peptide in marine molluscs. Invert. Surviv. J. 2010, 7, 157–164.
[14]  Rosa, R.D.; Barracco, M.A. Antimicrobial peptides in crustaceans. Invert. Surviv. J. 2010, 7, 262–284.
[15]  Matsunaga, S.; Fusetani, N.; Konosu, S. Bioactive marine metabolites, IV. Isolation and the amino acid composition of discodermin A, an antimicrobial peptide, from the marine sponge Discodermia kiiensis. J. Nat. Prod. 1985, 48, 236–241, doi:10.1021/np50038a006.
[16]  Otero-González, A.J.; Magalh?es, B.S.; Garcia-Villarino, M.; López-Abarratequi, C.; Sousa, D.A.; Dias, S.C.; Franco, O.L. Antimicrobial peptides from marine invertebrates as a new frontier for microbial infection control. FASEB J. 2010, 24, 1320–1334, doi:10.1096/fj.09-143388.
[17]  Noga, E.J.; Ullal, A.J.; Corrales, J.; Fernandes, J.M. Application of antimicrobial polypeptide host defenses to aquaculture: Exploitation of downregulation and upregulation responses. Comp. Biochem. Physiol. Part D 2011, 6, 44–54.
[18]  Rakers, S.; Niklasson, L.; Steinhagen, D.; Kruse, C.; Schauber, J.; Sundell, K.; Paus, R. Antimicrobial peptides (AMPs) from fish epidermis: Perspective for investigative dermatology. J. Invest. Dermatol. 2013, 133, 1140–1149, doi:10.1038/jid.2012.503.
[19]  Patrzykat, A.; Gallant, J.W.; Seo, J.K.; Pytyck, J.; Douglas, S.E. Novel antimicrobial peptides derived from flatfish genes. Antimicrob. Agents Chemother. 2003, 47, 2464–2470, doi:10.1128/AAC.47.8.2464-2470.2003.
[20]  Kim, J.Y.; Park, S.C.; Yoon, M.Y.; Hahm, K.S.; Park, Y. C-Terminal amidation of PMAP-23: Translocation to the inner membrane of Gram-negative bacteria. Amino Acids 2011, 40, 183–195, doi:10.1007/s00726-010-0632-1.
[21]  Gopal, R.; Park, J.S.; Seo, C.H.; Park, Y. Applications of circular dichroism for structural analysis of gelatin and antimicrobial peptides. Int. J. Mol. Sci. 2012, 13, 3229–3244, doi:10.3390/ijms13033229.
[22]  Findlay, B.; Zhanel, G.G.; Schweizer, F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob. Agents Chemother. 2010, 54, 4049–4058, doi:10.1128/AAC.00530-10.
[23]  Cole, A.M.; Darouiche, R.O.; Legarda, D.; Connell, N.; Diamond, G. Characterisation of a fish and antimicrobial peptide: Gene expression, subcellular localization, and spectrum of activity. Antimicrob. Agents Chemother. 2000, 44, 2039–2045, doi:10.1128/AAC.44.8.2039-2045.2000.
[24]  Cho, J.; Choi, H.; Lee, D.G. Influence of the N- and C-terminal regions of antimicrobial peptide plurocidin on antibacterial activity. J. Microbiol. Biotechnol. 2012, 22, 1367–1374, doi:10.4014/jmb.1205.05040.
[25]  Kolmer, H.L.; Taketomi, E.A.; Hazen, K.C.; Hughs, E.; Wilson, B.B.; Platts-Mills, T.A. Effect of combined and antifungal treatment in severe atopic dermatitis. J. Allergy Clin. Immunol. 1996, 98, 702–707, doi:10.1016/S0091-6749(96)70106-9.
[26]  National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard M7-A6; National Committee for Clinical Laboratory Standards: Wayne, PA, USA, 2003.
[27]  Jeong, N.; Kim, J.Y.; Park, S.C.; Lee, J.K.; Gopal, R.; Yoo, S.; Son, B.K.; Hahm, J.S.; Park, Y.; Hahm, K.S. Antibiotic and synergistic effect of Leu-Lys rich peptide against antibiotic resistant microoganisms isolated from patients with cholelithiasis. Biochem. Biophys. Res. Commun. 2010, 399, 581–586.
[28]  Maisetta, G.; di Luca, M.; Esin, S.; Florio, W.; Brancatisano, F.L.; Bottai, D.; Campa, M.; Batoni, G. Evaluation of the inhibitory effects of human serum components on bactericidal activity of human beta defensin 3. Peptides 2008, 29, 1–6, doi:10.1016/j.peptides.2007.10.013.
[29]  Goldman, M.J.; Anderson, G.M.; Stolzenberg, E.D.; Kari, U.P.; Zasloff, M.; Wilson, J.M. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88, 553–560, doi:10.1016/S0092-8674(00)81895-4.
[30]  Lee, I.H.; Cho, Y.; Lehrer, R.I. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect. Immun. 1997, 65, 2898–2903.
[31]  Bowdish, D.M.; Davidson, D.J.; Lau, Y.E.; Lee, K.; Scott, M.G.; Hancock, R.E. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 2005, 77, 451–459.
[32]  Tam, J.P.; Lu, Y.A.; Yang, J.L. Correlations of cationic charges with salt sensitivity and microbial specificity of cystine-stabilized β-strand antimicrobial peptides. J. Biol. Chem. 2002, 277, 50450–50456, doi:10.1074/jbc.M208429200.
[33]  H?iby, N.; Krogh Johansen, H.; Moser, C.; Song, Z.; Ciofu, O.; Kharazmi, A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001, 3, 23–35, doi:10.1016/S1286-4579(00)01349-6.
[34]  Pruitt, B.A., Jr.; McManus, A.T.; Kim, S.H.; Goodwin, C.W. Burn wound infections: Current status. World J. Surg. 1998, 22, 135–145, doi:10.1007/s002689900361.
[35]  Tredget, E.E.; Shankowsky, H.A.; Rennie, R.; Burrell, R.E.; Logsetty, S. Pseudomonas infections in the thermally injured patient. Burns 2004, 30, 3–26, doi:10.1016/j.burns.2003.08.007.
[36]  Steven, L.P.; Philip, G.B. Biofilms and their potential role in wound healing. Wounds 2004, 16, 234–240.
[37]  Jabalameli, F.; Mirsalehian, A.; Khoramian, B.; Aligholi, M.; Khoramrooz, S.S.; Asadollahi, P.; Taherikalani, M.; Emaneini, M. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns 2012, 38, 1192–1197, doi:10.1016/j.burns.2012.07.030.
[38]  Harrison-Balestra, C.; Cazzaniga, A.L.; Davis, S.C.; Mertz, P.M. A wound-isolated Pseudomonas aeruginosa grows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatol. Surg. 2003, 29, 631–635, doi:10.1046/j.1524-4725.2003.29146.x.
[39]  Serralta, V.W.; Harrison-Balestra, C.; Cazzaniga, A.L.; Davis, S.C.; Mertz, P.M. Lifestyles of bacteria in wounds: Presence of biofilms? Wounds 2001, 13, 29–34.
[40]  Schaber, J.A.; Triffo, W.J.; Suh, S.J.; Oliver, J.W.; Hastert, M.C.; Griswold, J.A.; Auer, M.; Hamood, A.N.; Rumbaugh, K.P. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect. Immun. 2007, 75, 3715–3721, doi:10.1128/IAI.00586-07.
[41]  Sauer, K.; Camper, K.; Ehrlich, G.D.; Costerton, J.W.; Davies, D.G. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J. Bacteriol. 2002, 184, 1140–1154, doi:10.1128/jb.184.4.1140-1154.2002.
[42]  Whiteley, M.; Bangera, M.G.; Bumgarner, R.E.; Parsek, M.R.; Teitzel, G.M.; Lory, S.; Greenberg, E.P. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001, 413, 860–864, doi:10.1038/35101627.
[43]  Vidaillac, C.; Benichou, L.; Duval, R.E. In vitro synergy of colistin combinations against colistin resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 2012, 56, 4856–4861, doi:10.1128/AAC.05996-11.
[44]  Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002, 15, 167–193, doi:10.1128/CMR.15.2.167-193.2002.
[45]  Sandoe, J.A.; Wysome, J.; West, A.P.; Heritage, J.; Wilcox, M.H. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against Enterococcal biofilms. J. Antimicrob. Chemother. 2006, 57, 767–770, doi:10.1093/jac/dkl013.
[46]  Evans, R.C.; Holmes, C.J. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicro. Agents Chemother. 1987, 31, 889–894, doi:10.1128/AAC.31.6.889.
[47]  Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.; Rehm, B.H.; Hancock, R.E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176–4182, doi:10.1128/IAI.00318-08.
[48]  Wei, G.X.; Campagna, A.N.; Bobek, L.A. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J. Antimicrob. Chemother. 2006, 57, 1100–1109, doi:10.1093/jac/dkl120.
[49]  Eckert, R.; Brady, K.M.; Greenberg, E.P.; Qi, F.; Yarbrough, D.K.; He, J.; McHardy, I.; Anderson, M.H.; Shi, W. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob. Agents Chemother. 2006, 50, 3833–3838, doi:10.1128/AAC.00509-06.
[50]  Pamp, S.J.; Gjermansen, M.; Johansen, H.K.; Tolker-Nielsen, T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 2008, 68, 223–240, doi:10.1111/j.1365-2958.2008.06152.x.
[51]  Nagant, C.; Pitts, B.; Nazmi, K.; Vandenbranden, M.; Bolscher, J.G.; Stewart, P.S.; Dehaye, J.P. Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments. Antimicrob. Agents Chemother. 2012, 56, 5698–5708, doi:10.1128/AAC.00918-12.
[52]  Choi, H.; Lee, D.G. Antimicrobial peptide pleurocidin synergizes with antibiotics through hydroxyl radical formation and membrane damage, and exerts antibiofilm activity. Biochim. Biophys. Acta 2012, 1820, 1831–1838, doi:10.1016/j.bbagen.2012.08.012.
[53]  Dartois, V.; Sanchez-Quesada, J.; Cabezas, E.; Chi, E.; Dubbelde, C.; Dunn, C.; Granja, J.; Gritzen, C.; Weinberger, D.; Ghadiri, M.R.; et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 2005, 49, 3302–3310, doi:10.1128/AAC.49.8.3302-3310.2005.
[54]  Bowler, P.G.; Welsby, S.; Towers, V.; Booth, R.; Hogarth, A.; Rowlands, V.; Joseph, A.; Jones, S.A. Multidrug reistant organisms, wounds and topical application. Int. Wound J. 2012, 9, 387–396, doi:10.1111/j.1742-481X.2012.00991.x.
[55]  Nidadavolu, P.; Amor, W.; Tran, P.L.; Dertien, J.; Colmer-Hamood, J.A.; Hamood, A.N. Garlic ointment inhibits biofilm formation by bacterial pathogens from burn wounds. J. Med. Microbiol. 2012, 61, 662–671, doi:10.1099/jmm.0.038638-0.
[56]  Ngo, Q.D.; Vickery, K.; Deva, A.K. The effect of topical negative pressure on wound biofilms using an in vitro wound model. Wound Repair Regen. 2012, 20, 83–90, doi:10.1111/j.1524-475X.2011.00747.x.
[57]  Ryu, S.; Choi, S.Y.; Acharya, S.; Chun, Y.J.; Gurley, C.; Park, Y.; Armstrong, C.A.; Song, P.I.; Kim, B.J. Antimicrobial and anti-inflammatory effects of cecropin A (1-8)-magainin 2(1-12) hybrid peptide analog P5 against Malassezia furfur infection in human ketatinocytes. J. Invest. Dermatol. 2011, 131, 1677–1683, doi:10.1038/jid.2011.112.
[58]  Javadpour, M.M.; Juban, M.M.; Lo, W.C.; Bishop, S.M.; Alberty, J.B.; Cowell, S.M.; Becker, C.L.; Mclaughlin, M.L. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 1996, 39, 3107–3113, doi:10.1021/jm9509410.
[59]  Fernandez-Lopez, S.; Kim, H.S.; Choi, E.C.; Delgado, M.; Granja, J.R.; Khasanov, A.; Kraehenbuehl, K.; Long, G.; Weinberger, D.A.; Wilcoxen, K.M.; et al. Antibacterial agents based on the cyclic d,l-α-peptide architecture. Nature 2001, 412, 452–455, doi:10.1038/35086601.
[60]  Chan, D.I.; Prenner, E.J.; Vogel, H.J. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochim. Biophys. Acta 2006, 1758, 1184–1202, doi:10.1016/j.bbamem.2006.04.006.
[61]  Schibli, D.J.; Hwang, P.M.; Vogel, H.J. The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett. 1999, 446, 213–217, doi:10.1016/S0014-5793(99)00214-8.
[62]  Jing, W.; Hunter, H.N.; Hagel, J.; Vogel, H.J. The structure of the antimicrobial peptide Ac-RRWWRF-NH2 bound to micelles and its interactions with phospholipid bilayers. J. Pept. Res. 2003, 61, 219–229.
[63]  Glukhov, E.; Stark, M.; Burrows, L.L.; Deber, C.M. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem. 2005, 280, 33960–33967.
[64]  Andra, J.; Monreal, D.; Martinez de Tejada, G.; Olak, C.; Brezesinski, G.; Gomez, S.S.; Goldmann, T.; Bartels, R.; Brandenburg, K.; Moriyon, I. Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. J. Biol. Chem. 2007, 282, 14719–14728, doi:10.1074/jbc.M608920200.
[65]  Hawrani, A.; Howe, R.A.; Walsh, T.R.; Dempsey, C.E. Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. J. Biol. Chem. 2008, 283, 18636–18645.
[66]  Gopal, R.; Park, S.C.; Ha, K.J.; Cho, S.J.; Kim, S.W.; Song, P.I.; Nah, J.W.; Park, Y.; Hahm, K.S. Effect of Leucine and Lysine substitution on the antimicrobial activity and evaluation of the mechanism of the HPA3NT3 analog peptide. J. Pept. Sci. 2009, 15, 589–594, doi:10.1002/psc.1155.
[67]  Pandey, B.K.; Ahmad, A.; Asthana, N.; Azmi, S.; Srivastava, R.M.; Srivastava, S.; Verma, R.; Vishwakarma, A.L.; Ghosh, J.K. Cell-selective lysis by novel analogues of melittin against human red blood cells and Escherichia coli. Biochemistry 2010, 49, 7920–7929, doi:10.1021/bi100729m.
[68]  Gopal, R.; Seo, C.H.; Song, P.I.; Park, Y. Effect of repetitive lysine-tryptophan motifs on the bactericidal activity of antimicrobial peptides. Amino Acids 2013, 44, 645–660, doi:10.1007/s00726-012-1388-6.
[69]  Gill, S.C.; von Hippel, P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1989, 182, 319–326, doi:10.1016/0003-2697(89)90602-7.
[70]  Park, S.C.; Kim, J.Y.; Lee, J.K.; Hwang, I.; Cheong, H.; Nah, J.W.; Hahm, K.S.; Park, Y. Antifungal mechanism of a novel antifungal protein from pumpkin rinds against various fungal pathogens. J. Agric. Food. Chem. 2009, 57, 9299–9304.
[71]  Rolli, E.; Ragni, E.; de Medina-Redondo, M.; Arroyo, J.; de Aldana, C.R.; Popolo, L. Expression, stability, and replacement of glucan-remodeling enzymes during developmental transition in Saccharomyces cerevisiae. Mol. Biol. Cell. 2011, 22, 1585–1598, doi:10.1091/mbc.E10-03-0268.
[72]  Gopal, R.; Na, H.; Seo, C.H.; Park, Y. Antifungal activity of (KW)n or (RW)n peptide against Fusarium solani and Fusarium oxysporum. Int. J. Mol. Sci. 2012, 13, 15042–15053, doi:10.3390/ijms131115042.
[73]  Christensen, G.D.; Simpson, W.A.; Younger, J.J.; Baddour, F.F.; Barrett, D.M.; Melton, D.M.; Beachey, E.H. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: A quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 1985, 22, 996–1006.
[74]  Mayer, L.D.; Hope, M.J.; Cullis, P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochem. Biophys. Acta 1986, 858, 161–168, doi:10.1016/0005-2736(86)90302-0.
[75]  Stewart, J.C.M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 1980, 104, 10–14.
[76]  Gopal, R.; Lee, J.K.; Lee, J.H.; Kim, Y.G.; Oh, G.C.; Seo, C.H.; Park, Y. Effect of repetitive lysine-tryptophan motifs on the eukaryotic membrane. Int. J. Mol. Sci. 2013, 14, 2190–2202, doi:10.3390/ijms14012190.
[77]  Chongsiriwatana, N.P.; Barron, A.E. Comparing bacterial membrane interactions of antimicrobial peptides and their mimics. Methods Mol. Biol. 2010, 618, 171–182, doi:10.1007/978-1-60761-594-1_12.
[78]  Allen, T.M.; Cleland, L.G. Serum-induced leakage of liposome contents. Biochim. Biophys. Acta 1980, 10, 418–426.

Full-Text

comments powered by Disqus